Reverse Medical wins FDA approval to launch U.S. clinical trials of its Barrel vascular reconstruction device for use in treating aneurysms.
California-based Reverse Medical landed key FDA approval to launch U.S. clinical trials of its Barrel vascular reconstruction device for treatment of intracranial bifurcation aneurysms.
The company plans to finalize its trial structure "very soon" and begin enrolling patients within the next few months, president & CEO Jeffrey Valko said in prepared remarks.
Analogic says it won 510(k) clearance from the FDA for its Sonic Window, a handheld ultrasound device for visualizing the vasculature for peripheral IV access.
Analogic (NSDQ:ALOG) said it won 510(k) clearance from the FDA for its handheld Sonic Window ultrasound device, designed to help caregivers view the vasculature to guide peripheral IV placement.
Bi02 Medical, which makes the Angel vena cava filter catheter, reports a nearly $6 million equity round.
Bi02 Medical, maker of the Angel vena cava filter catheter, said it raised nearly $5.9 million in a hoped-for $7.5 million equity offering.
The funding round for the San Antonio, Texas-based medical device company involved 10 unnamed investors, according to a regulatory filing.
New York's AngioDynamics wins updated labeling from FDA regulators, indicating its AngioVac venous drainage system for up to 6 hours at a time.
AngioDynamics (NSDQ:ANGO) tallied a new win for its AngioVac drainage system, with new FDA clearance to market the device for extended use.
New York's AngioDynamics lands FDA clearance for a new BioFlo product and takes charge of distribution partner Medcomp's Celerity tip locater after an FDA loss.
LeMaitre Vascular says it plans to lay off about 10% of its workforce, or roughly 30 workers, despite posting record sales during the 4th quarter.
LeMaitre Vascular (NSDQ:LMAT) said it plans to lay off about 10% of its workforce, or about 30 employees, even as it comes off of a record sales performance during the 4th quarter.
Evena Medical says it pulled in $5 million in a Series B it hopes will eventually reach $15 million and announced a distribution deal in the Middle East for its Eyes-On vascular imaging glasses.
Evena Medical said it landed $5 million in a Series B funding round and inked a distribution deal in the Middle East and North Africa.
Silicon Valley-based Evena said it hopes the financing round will eventually reach $15 million. This tranche of the round comes from its new, unnamed distribution partner in 15 Middle Eastern and North African countries.